Alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof

Patent metadata

Field	Value
Publication number	US-10869922-B2
Application number	US-201616300295-A
Country	US
Kind code	B2
Filing date	Oct 14, 2016
Priority date	May 13, 2016
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like.

First claim

The invention claimed is:

1. A compound immunologic adjuvant comprising alhydrogel and sodium chloride, wherein a final mass fraction of the sodium chloride is 2.7%-4.5%.

2. The compound immunologic adjuvant according to claim 1 , wherein the final mass fraction of the sodium chloride is 3.6%.

3. The compound immunologic adjuvant according to claim 1 , wherein a particle size of the alhydrogel ranges from 1 μm to 10 μm.

4. An immunologic adjuvant-antigen complex, characterized by comprising an antigen and the compound immunologic adjuvant according to claim 1 .

5. The immunologic adjuvant-antigen complex according to claim 4 , wherein a ratio of the antigen to the alhydrogel in the compound immunologic adjuvant is 1:1-100 by weight.

6. The immunologic adjuvant-antigen complex according to claim 5 , wherein the ratio of the antigen to the the alhydrogel is 1:5-50 by weight.

7. The immunologic adjuvant-antigen complex according to claim 4 , wherein the antigen is at least one of a tumor antigen, a virus antigen or a bacterial antigen.

8. The immunologic adjuvant-antigen complex according to claim 7 , wherein the tumor antigen is selected from at least one of OVA tumor model antigen, NY-ESO-1, human melanoma-associated antigen gP100, melanoma antigen mage-1 or carcinoembryonic antigen.

9. The immunologic adjuvant-antigen complex according to claim 7 , wherein the virus antigen is at least one member selected from the group consisting of hepatitis B virus antigen, hepatitis A virus antigen, hepatitis C virus antigen, poliovirus antigen, rabies virus antigen, yellow fever virus antigen, HIV antigen, measles antigen, mumps antigen, rubella antigen, chicken pox antigen, rotavirus antigen, Japanese encephalitis antigen, papillomavirus antigen, epidemic hemorrhagic fever virus antigen and plague virus antigen.

10. The immunologic adjuvant-antigen complex according to claim 7 , wherein the bacterial antigen is at least one member selected from the group consisting of Staphylococcus aureus antigen, Pseudomonas aeruginosa antigen, pertussis antigen, diphtheria antigen, Haemophilus influenzae antigen, Neisseria meningitidis antigen, tetanus toxoid antigen, Streptococcus hemolyticus antigen, Streptococcus non- hemolyticus antigen, Pneumococcus antigen, Tubercle bacillus antigen, Bacillus anthracis antigen, Vibrio cholerae antigen, Leptospira antigen and Helicobacter pylori antigen.

11. A method for preparing the immunologic adjuvant-antigen complex according to claim 4 , said method comprising the following steps:
a. diluting or dissolving the antigen in water;
b. adding the sodium chloride, and uniformly mixing;
c. adding the alhydrogel, and uniformly mixing.

12. A method for preparing the immunologic adjuvant-antigen complex according to claim 4 , said method comprising the following steps:
a. adding the sodium chloride to an alhydrogel adjuvant to prepare a stock solution for a hypertonic alhydrogel compound adjuvant;
b. diluting or dissolving the antigen in water;
c. adding the hypertonic alhydrogel compound adjuvant, and uniformly mixing.

13. A method for preparing a vaccine, said method comprising combining sodium chloride and water fro injection and allowing a mass fraction of sodium chloride to reach 2.7%-4.5% before the vaccine is used, wherein said method comprises the following steps:
adding the water for injection and the sodium chloride to an antigen, then adding an alhydrogel adjuvant, and allowing the mass fraction of sodium chloride in the prepared vaccine to reach 2.7%-4.5% before the vaccine is used;
or directly dissolving the antigen in water, adding a hypertonic alhydrogel stock solution, and allowing the mass fraction of sodium chloride in the prepared vaccine to reach 2.7%-4.5%;
or directly adding an adjuvant of sodium chloride in the preparation process, and allowing the mass fraction of sodium chloride in the prepared vaccine to reach 2.7%-4.5% before injection, if the vaccine to be prepared already contains the antigen and the alhydrogel.

14. A method for preparing a vaccine, said method comprising combining sodium chloride and water for injection, wherein a final mass fraction of the sodium chloride in the prepared vaccine is 3.6%.

15. The method for preparing a vaccine according to claim 13 , wherein a ratio of the antigen to the alhydrogel in the prepared vaccine is 1:1-100 by weight.

16. The method for preparing a vaccine according to claim 15 , wherein the ratio of the antigen to the the alhydrogel in the prepared vaccine is 1:5-50 by weight.

Assignees

• Univ Sichuan

Inventors

• Wei Xiawei
• Luo Min
• Wei Yuquan

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• A61P31/20 Primary

  for DNA viruses · CPC title

• A61K39/29

  Hepatitis virus · CPC title

• A61K39/12

  Viral antigens · CPC title

• C12N2730/10134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title